Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.

IMPORTANCE OF THE FIELD: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. AREAS COVERED IN THIS REVIEW: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. WHAT THE READER WILL GAIN: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. TAKE HOME MESSAGE: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

Gender-specific echocardiographic findings in nonagenarians with cardiovascular disease.

Echocardiographic findings in the fastest growing segment of our population, the very elderly, are limited in the literature. We performed a retrospective analysis of 431 consecutive nonagenarians who underwent transthoracic echocardiography (2-dimensional, M-mode, pulse and continuous wave Doppler with color flow mapping) at our center. Mean age was 92.4 years, with women being the majority (73% vs 27%). Men were more likely than women to have coronary artery disease (45% vs 36%, p = 0.03), impaired left ventricular (LV) ejection fraction (51% vs 40%, p <0.04), lower mean LV ejection fraction (50% vs 54%, p = 0.01), and regional wall motion abnormalities (31% vs 19%, p = 0.009). Women were much more likely than men to have hypertension (76% vs 52%, p = <0.0001), LV hypertrophy (82% vs 72%, p <0.001), severe left atrial enlargement (31% vs 16%, p = 0.004), moderate to severe mitral annular calcification (22% vs 10, p = 0.006), and tricuspid regurgitation (70% vs 51, p = 0.002). In this, largest to date, study of echocardiographic findings in nonagenarians, abnormal findings were much more common than previously reported. Men were more likely to have coronary artery disease and related findings, whereas women were more likely to have hypertension and related findings.